153 related articles for article (PubMed ID: 28933000)
1. Evaluation of current prediction models for Lynch syndrome: updating the PREMM5 model to identify PMS2 mutation carriers.
Goverde A; Spaander MCW; Nieboer D; van den Ouweland AMW; Dinjens WNM; Dubbink HJ; Tops CJ; Ten Broeke SW; Bruno MJ; Hofstra RMW; Steyerberg EW; Wagner A
Fam Cancer; 2018 Jul; 17(3):361-370. PubMed ID: 28933000
[TBL] [Abstract][Full Text] [Related]
2. Development and Validation of the PREMM
Kastrinos F; Uno H; Ukaegbu C; Alvero C; McFarland A; Yurgelun MB; Kulke MH; Schrag D; Meyerhardt JA; Fuchs CS; Mayer RJ; Ng K; Steyerberg EW; Syngal S
J Clin Oncol; 2017 Jul; 35(19):2165-2172. PubMed ID: 28489507
[TBL] [Abstract][Full Text] [Related]
3. Prediction of Lynch syndrome in consecutive patients with colorectal cancer.
Green RC; Parfrey PS; Woods MO; Younghusband HB
J Natl Cancer Inst; 2009 Mar; 101(5):331-40. PubMed ID: 19244167
[TBL] [Abstract][Full Text] [Related]
4. Comparison of Prediction Models for Lynch Syndrome Among Individuals With Colorectal Cancer.
Kastrinos F; Ojha RP; Leenen C; Alvero C; Mercado RC; Balmaña J; Valenzuela I; Balaguer F; Green R; Lindor NM; Thibodeau SN; Newcomb P; Win AK; Jenkins M; Buchanan DD; Bertario L; Sala P; Hampel H; Syngal S; Steyerberg EW;
J Natl Cancer Inst; 2016 Feb; 108(2):. PubMed ID: 26582061
[TBL] [Abstract][Full Text] [Related]
5. SNP association study in PMS2-associated Lynch syndrome.
Ten Broeke SW; Elsayed FA; Pagan L; Olderode-Berends MJW; Garcia EG; Gille HJP; van Hest LP; Letteboer TGW; van der Kolk LE; Mensenkamp AR; van Os TA; Spruijt L; Redeker BJW; Suerink M; Vos YJ; Wagner A; Wijnen JT; Steyerberg EW; Tops CMJ; van Wezel T; Nielsen M
Fam Cancer; 2018 Oct; 17(4):507-515. PubMed ID: 29147930
[TBL] [Abstract][Full Text] [Related]
6. Lessons learnt from implementation of a Lynch syndrome screening program for patients with gynaecological malignancy.
Najdawi F; Crook A; Maidens J; McEvoy C; Fellowes A; Pickett J; Ho M; Nevell D; McIlroy K; Sheen A; Sioson L; Ahadi M; Turchini J; Clarkson A; Hogg R; Valmadre S; Gard G; Dooley SJ; Scott RJ; Fox SB; Field M; Gill AJ
Pathology; 2017 Aug; 49(5):457-464. PubMed ID: 28669579
[TBL] [Abstract][Full Text] [Related]
7. PMS2 expression decrease causes severe problems in mismatch repair.
Kasela M; Nyström M; Kansikas M
Hum Mutat; 2019 Jul; 40(7):904-907. PubMed ID: 30946512
[TBL] [Abstract][Full Text] [Related]
8. Commentary: PREMM5 threshold of 2.5% is recommended to improve identification of PMS2 carriers.
Kastrinos F; Uno H; Syngal S
Fam Cancer; 2018 Oct; 17(4):567. PubMed ID: 29380099
[No Abstract] [Full Text] [Related]
9. Comparison of Colorectal and Endometrial Microsatellite Instability Tumor Analysis and Premm
Mannucci A; Furniss CS; Ukaegbu C; Horiguchi M; Fehlmann T; Uno H; Yurgelun MB; Syngal S
J Clin Oncol; 2020 Dec; 38(34):4086-4094. PubMed ID: 32997573
[TBL] [Abstract][Full Text] [Related]
10. A validation of models for prediction of pathogenic variants in mismatch repair genes.
Shyr C; Blackford AL; Huang T; Ke J; Ouardaoui N; Trippa L; Syngal S; Ukaegbu C; Uno H; Nafa K; Stadler ZK; Offit K; Amos CI; Lynch PM; Chen S; Giardiello FM; Buchanan DD; Hopper JL; Jenkins MA; Southey MC; Win AK; Figueiredo JC; Braun D; Parmigiani G
Genet Med; 2022 Oct; 24(10):2155-2166. PubMed ID: 35997715
[TBL] [Abstract][Full Text] [Related]
11. Cancer Risks for PMS2-Associated Lynch Syndrome.
Ten Broeke SW; van der Klift HM; Tops CMJ; Aretz S; Bernstein I; Buchanan DD; de la Chapelle A; Capella G; Clendenning M; Engel C; Gallinger S; Gomez Garcia E; Figueiredo JC; Haile R; Hampel HL; Hopper JL; Hoogerbrugge N; von Knebel Doeberitz M; Le Marchand L; Letteboer TGW; Jenkins MA; Lindblom A; Lindor NM; Mensenkamp AR; Møller P; Newcomb PA; van Os TAM; Pearlman R; Pineda M; Rahner N; Redeker EJW; Olderode-Berends MJW; Rosty C; Schackert HK; Scott R; Senter L; Spruijt L; Steinke-Lange V; Suerink M; Thibodeau S; Vos YJ; Wagner A; Winship I; Hes FJ; Vasen HFA; Wijnen JT; Nielsen M; Win AK
J Clin Oncol; 2018 Oct; 36(29):2961-2968. PubMed ID: 30161022
[TBL] [Abstract][Full Text] [Related]
12. Clinical and Molecular Characterization of Brazilian Patients Suspected to Have Lynch Syndrome.
Carneiro da Silva F; Ferreira JR; Torrezan GT; Figueiredo MC; Santos ÉM; Nakagawa WT; Brianese RC; Petrolini de Oliveira L; Begnani MD; Aguiar-Junior S; Rossi BM; Ferreira Fde O; Carraro DM
PLoS One; 2015; 10(10):e0139753. PubMed ID: 26437257
[TBL] [Abstract][Full Text] [Related]
13. Isolated Loss of PMS2 Immunohistochemical Expression is Frequently Caused by Heterogenous MLH1 Promoter Hypermethylation in Lynch Syndrome Screening for Endometrial Cancer Patients.
Kato A; Sato N; Sugawara T; Takahashi K; Kito M; Makino K; Sato T; Shimizu D; Shirasawa H; Miura H; Sato W; Kumazawa Y; Sato A; Kumagai J; Terada Y
Am J Surg Pathol; 2016 Jun; 40(6):770-6. PubMed ID: 26848797
[TBL] [Abstract][Full Text] [Related]
14. Comprehensive Mutation Analysis of PMS2 in a Large Cohort of Probands Suspected of Lynch Syndrome or Constitutional Mismatch Repair Deficiency Syndrome.
van der Klift HM; Mensenkamp AR; Drost M; Bik EC; Vos YJ; Gille HJ; Redeker BE; Tiersma Y; Zonneveld JB; García EG; Letteboer TG; Olderode-Berends MJ; van Hest LP; van Os TA; Verhoef S; Wagner A; van Asperen CJ; Ten Broeke SW; Hes FJ; de Wind N; Nielsen M; Devilee P; Ligtenberg MJ; Wijnen JT; Tops CM
Hum Mutat; 2016 Nov; 37(11):1162-1179. PubMed ID: 27435373
[TBL] [Abstract][Full Text] [Related]
15. Performance of Lynch syndrome predictive models in a multi-center US referral population.
Khan O; Blanco A; Conrad P; Gulden C; Moss TZ; Olopade OI; Kupfer SS; Terdiman J
Am J Gastroenterol; 2011 Oct; 106(10):1822-7; quiz 1828. PubMed ID: 21747416
[TBL] [Abstract][Full Text] [Related]
16. Mismatch repair gene mutation spectrum in the Swedish Lynch syndrome population.
Lagerstedt-Robinson K; Rohlin A; Aravidis C; Melin B; Nordling M; Stenmark-Askmalm M; Lindblom A; Nilbert M
Oncol Rep; 2016 Nov; 36(5):2823-2835. PubMed ID: 27601186
[TBL] [Abstract][Full Text] [Related]
17. Molecular Background of Colorectal Tumors From Patients With Lynch Syndrome Associated With Germline Variants in PMS2.
Ten Broeke SW; van Bavel TC; Jansen AML; Gómez-García E; Hes FJ; van Hest LP; Letteboer TGW; Olderode-Berends MJW; Ruano D; Spruijt L; Suerink M; Tops CM; van Eijk R; Morreau H; van Wezel T; Nielsen M
Gastroenterology; 2018 Sep; 155(3):844-851. PubMed ID: 29758216
[TBL] [Abstract][Full Text] [Related]
18. Semiquantitative assessment of immunohistochemistry for mismatch repair proteins in Lynch syndrome.
Barrow E; Jagger E; Brierley J; Wallace A; Evans G; Hill J; McMahon R
Histopathology; 2010 Feb; 56(3):331-44. PubMed ID: 20459533
[TBL] [Abstract][Full Text] [Related]
19. Heterozygous mutations in PMS2 cause hereditary nonpolyposis colorectal carcinoma (Lynch syndrome).
Hendriks YM; Jagmohan-Changur S; van der Klift HM; Morreau H; van Puijenbroek M; Tops C; van Os T; Wagner A; Ausems MG; Gomez E; Breuning MH; Bröcker-Vriends AH; Vasen HF; Wijnen JT
Gastroenterology; 2006 Feb; 130(2):312-22. PubMed ID: 16472587
[TBL] [Abstract][Full Text] [Related]
20. Validation of Prediction Models for Mismatch Repair Gene Mutations in Koreans.
Lee SY; Kim DW; Shin YK; Ihn MH; Lee SM; Oh HK; Ku JL; Jeong SY; Lee JB; Ahn S; Won S; Kang SB
Cancer Res Treat; 2016 Apr; 48(2):668-75. PubMed ID: 26044159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
